$BNTC
Benitec Biopharma Inc.

2020 Q4 Form 10-Q Financial Statement

#000119312520292209 Filed on November 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $1.000K $55.00K $33.00K
YoY Change -98.7% 66.67%
Cost Of Revenue -$20.00K $130.0K $30.00K
YoY Change -93.71% 333.33%
Gross Profit $20.00K -$80.00K $10.00K
YoY Change -95.47% -900.0%
Gross Profit Margin 2000.0% -145.45% 30.3%
Selling, General & Admin $2.110M $1.840M $750.0K
YoY Change -45.78% 145.33%
% of Gross Profit 10550.0% 7500.0%
Research & Development $1.168M $774.0K $423.0K
YoY Change 94.99% 82.98%
% of Gross Profit 5840.0% 4230.0%
Depreciation & Amortization $67.00K $45.00K $51.00K
YoY Change 31.37% -11.76%
% of Gross Profit 335.0% 510.0%
Operating Expenses $3.260M $2.745M $1.199M
YoY Change 48.99% 128.94%
Operating Profit -$3.259M -$2.690M -$1.166M
YoY Change 54.38% 130.7%
Interest Expense -$2.000K -$1.000K $18.00K
YoY Change -111.76% -105.56%
% of Operating Profit
Other Income/Expense, Net $7.000K -$28.00K $19.00K
YoY Change -66.67% -247.37%
Pretax Income -$3.250M -$2.720M -$1.150M
YoY Change -10.95% 136.52%
Income Tax
% Of Pretax Income
Net Earnings -$3.252M -$2.718M -$1.147M
YoY Change 55.6% 136.97%
Net Earnings / Revenue -325200.0% -4941.82% -3475.76%
Basic Earnings Per Share
Diluted Earnings Per Share -$755.8K -$2.450M -$22.99
COMMON SHARES
Basic Shares Outstanding 4.405M 1.108M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.01M $7.450M
YoY Change 0.79%
Cash & Equivalents $14.01M $7.450M $16.63M
Short-Term Investments
Other Short-Term Assets $352.0K $588.0K
YoY Change -37.14%
Inventory
Prepaid Expenses $538.0K $564.0K
Receivables $20.00K $20.00K
Other Receivables $21.00K $0.00
Total Short-Term Assets $14.38M $8.056M
YoY Change -6.54%
LONG-TERM ASSETS
Property, Plant & Equipment $610.0K $503.0K
YoY Change -35.79%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $10.00K $10.00K
YoY Change 0.0%
Other Assets $210.0K $10.00K
YoY Change
Total Long-Term Assets $1.129M $860.0K
YoY Change 17.6%
TOTAL ASSETS
Total Short-Term Assets $14.38M $8.056M
Total Long-Term Assets $1.129M $860.0K
Total Assets $15.51M $8.916M
YoY Change -5.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $90.00K $300.0K
YoY Change -10.0%
Accrued Expenses $600.0K $610.0K
YoY Change 275.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $779.0K $1.019M
YoY Change 2.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $110.0K $160.0K
YoY Change
Total Long-Term Liabilities $110.0K $160.0K
YoY Change -66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities $779.0K $1.019M
Total Long-Term Liabilities $110.0K $160.0K
Total Liabilities $887.0K $1.180M
YoY Change -18.62%
SHAREHOLDERS EQUITY
Retained Earnings -$122.2M -$119.3M
YoY Change
Common Stock $138.4M $128.9M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $14.63M $7.736M $16.97M
YoY Change
Total Liabilities & Shareholders Equity $15.51M $8.916M
YoY Change -5.13%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income -$3.252M -$2.718M -$1.147M
YoY Change 55.6% 136.97%
Depreciation, Depletion And Amortization $67.00K $45.00K $51.00K
YoY Change 31.37% -11.76%
Cash From Operating Activities -$3.330M -$2.360M -$545.0K
YoY Change -17.09% 333.03%
INVESTING ACTIVITIES
Capital Expenditures -$180.0K $173.0K -$60.00K
YoY Change 98.46% -388.33%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $80.00K
YoY Change -100.0% -100.0%
Cash From Investing Activities -$180.0K -$173.0K $1.000K
YoY Change 100.17% -17400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $2.250M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.850M 0.000 1.770M
YoY Change 412.15% -100.0%
NET CHANGE
Cash From Operating Activities -3.330M -2.360M -545.0K
Cash From Investing Activities -180.0K -173.0K 1.000K
Cash From Financing Activities 9.850M 0.000 1.770M
Net Change In Cash 6.340M -2.533M 1.226M
YoY Change -390.43% -306.61%
FREE CASH FLOW
Cash From Operating Activities -$3.330M -$2.360M -$545.0K
Capital Expenditures -$180.0K $173.0K -$60.00K
Free Cash Flow -$3.150M -$2.533M -$485.0K
YoY Change -19.76% 422.27%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7450000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9801000
CY2020Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
18000
CY2020Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
59000
CY2020Q3 us-gaap Other Assets Current
OtherAssetsCurrent
588000
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
949000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
8056000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
774000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
423000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1837000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
750000
CY2020Q2 us-gaap Deposit Assets
DepositAssets
9000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
348000
CY2020Q3 us-gaap Assets
Assets
8916000
CY2020Q2 us-gaap Assets
Assets
11587000
CY2020Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
624000
CY2020Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
741000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
197000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
203000
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
198000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1019000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1136000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
10809000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
503000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
374000
CY2020Q3 us-gaap Deposit Assets
DepositAssets
9000
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
161000
CY2020Q3 us-gaap Liabilities
Liabilities
1180000
CY2020Q2 us-gaap Liabilities
Liabilities
1349000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
1000
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
128850000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
128826000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-119340000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116636000
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1775000
CY2020Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1953000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
7736000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
10238000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8916000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11587000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2718000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-1147000
CY2020Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45000
CY2019Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
51000
CY2020Q3 bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
47000
CY2019Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-1000
CY2020Q3 us-gaap Share Based Compensation
ShareBasedCompensation
38000
CY2019Q3 us-gaap Share Based Compensation
ShareBasedCompensation
55000
CY2020Q3 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-27000
CY2019Q3 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-974000
CY2020Q3 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-374000
CY2019Q3 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-130000
CY2020Q3 bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
-119000
CY2019Q3 bntc Increasedecrease In Accounts And Other Payables
IncreasedecreaseInAccountsAndOtherPayables
-645000
CY2020Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-8000
CY2019Q3 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
18000
CY2020Q3 bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-46000
CY2020Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2360000
CY2019Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-545000
CY2020Q3 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
173000
CY2020Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
55000
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
33000
CY2020Q3 us-gaap Revenues
Revenues
55000
CY2019Q3 us-gaap Revenues
Revenues
33000
CY2020Q3 bntc Royalties And License Fees
RoyaltiesAndLicenseFees
134000
CY2019Q3 bntc Royalties And License Fees
RoyaltiesAndLicenseFees
26000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
2745000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
1199000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2690000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1166000
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-54000
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0
CY2020Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1000
CY2019Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
18000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
27000
CY2020Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
0
CY2019Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-28000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19000
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
178000
CY2019Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-304000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
178000
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-304000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2540000
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1451000
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.45
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.34
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1108374
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
858794
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
55000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
38000
CY2019Q3 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1000
CY2020Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-173000
CY2019Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1000
CY2020Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2533000
CY2019Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashAndCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
1226000
CY2020Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
182000
CY2019Q3 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-313000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16631000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1720000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
16968000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
145421
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
65852
CY2020Q3 us-gaap Due From Banks
DueFromBanks
7450000
CY2020Q2 us-gaap Due From Banks
DueFromBanks
5231000
CY2020Q3 us-gaap Time Deposits At Carrying Value
TimeDepositsAtCarryingValue
0
CY2020Q2 us-gaap Time Deposits At Carrying Value
TimeDepositsAtCarryingValue
4570000
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
564000
CY2020Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
861000
CY2020Q3 us-gaap Security Deposit
SecurityDeposit
14000
CY2020Q2 us-gaap Security Deposit
SecurityDeposit
69000
CY2020Q3 bntc Otherdeposits
Otherdeposits
9000
CY2020Q2 bntc Otherdeposits
Otherdeposits
18000
CY2020Q3 bntc Market Value Of Listed Shares
MarketValueOfListedShares
1000
CY2020Q2 bntc Market Value Of Listed Shares
MarketValueOfListedShares
1000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1344000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1170000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
841000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
796000
CY2020Q3 us-gaap Depreciation
Depreciation
45000
CY2020Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
299000
CY2020Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
282000
CY2019Q3 us-gaap Depreciation
Depreciation
51000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
218000
CY2020Q3 bntc Accrued Licence Fees Current
AccruedLicenceFeesCurrent
171000
CY2020Q2 bntc Accrued Licence Fees Current
AccruedLicenceFeesCurrent
54000
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
43000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
155000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
111000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
250000
CY2020Q3 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P1Y8M12D
CY2020Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0467
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
156000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
375000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
16000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
359000
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
145421
CY2020Q2 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
29.48
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
38000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
55000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
119000
CY2020Q3 dei Document Type
DocumentType
10-Q
CY2020Q3 dei Amendment Flag
AmendmentFlag
false
CY2020Q3 dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
107095
CY2020Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2020Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q3 dei Entity Registrant Name
EntityRegistrantName
Benitec Biopharma Inc.
CY2020Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001808898
CY2020Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2020Q3 bntc Weighted Average Exercise Price Of Class Of Warrants Or Rights Outstanding
WeightedAverageExercisePriceOfClassOfWarrantsOrRightsOutstanding
10.50
CY2020Q3 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q3 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q3 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2020Q3 dei Document Transition Report
DocumentTransitionReport
false
CY2020Q3 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020Q3 dei Entity Address Address Line1
EntityAddressAddressLine1
3940 Trust Way Hayward
CY2020Q3 dei Entity Address Country
EntityAddressCountry
CA
CY2020Q3 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94545
CY2020Q3 dei City Area Code
CityAreaCode
(510)
CY2020Q3 dei Local Phone Number
LocalPhoneNumber
780-0819
CY2020Q3 dei Security12b Title
Security12bTitle
Common stock
CY2020Q3 dei Trading Symbol
TradingSymbol
BNTC
CY2020Q3 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2020Q3 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q3 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q3 dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4405469
CY2020Q3 dei Entity File Number
EntityFileNumber
001-39267
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
395000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
192000
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
213000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1108374
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1108374
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2020Q3 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-11-22
CY2019Q4 bntc Common Stock Shares Redomiciliation Description
CommonStockSharesRedomiciliationDescription
one Benitec Biopharma Inc. share for every 300 BBL shares
CY2019Q3 bntc Amortization Of Right Of Use Assets
AmortizationOfRightOfUseAssets
46000
CY2019Q3 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
1000
CY2019Q3 bntc Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-27000
CY2019Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2250000
CY2019Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
480000
CY2019Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1770000
CY2019Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
579000
CY2019Q3 bntc Issuance And Exercise Of Prefunded Warrants Net Of Transaction Costs
IssuanceAndExerciseOfPrefundedWarrantsNetOfTransactionCosts
50000
CY2020Q3 bntc Class Of Warrants Or Rights Grants In Period
ClassOfWarrantsOrRightsGrantsInPeriod
0
CY2020Q3 bntc Weighted Average Exercise Price Of Class Of Warrants Or Granted During The Period
WeightedAverageExercisePriceOfClassOfWarrantsOrGrantedDuringThePeriod
0
CY2020Q3 bntc Class Of Warrants Or Rights Excercised During The Period
ClassOfWarrantsOrRightsExcercisedDuringThePeriod
0
CY2020Q3 bntc Weighted Average Exercise Price Of Class Of Warrants Or Exercised During The Period
WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriod
0
CY2020Q3 bntc Class Of Warrants Or Rights Cashless Exercise Of Warrants
ClassOfWarrantsOrRightsCashlessExerciseOfWarrants
38326
CY2020Q3 bntc Weighted Average Exercise Price Of Class Of Warrants Or Exercised During The Period Cash Less Exercise Of Warrants
WeightedAverageExercisePriceOfClassOfWarrantsOrExercisedDuringThePeriodCashLessExerciseOfWarrants
82.50
CY2020Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
52000000
CY2019Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
52000000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
16594000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15718000
CY2020Q3 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020Q4 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
3709676
CY2020Q4 bntc Common Stock Equivalents
CommonStockEquivalents
2666644
CY2020Q4 bntc Gross Proceeds From Issue Of Stock
GrossProceedsFromIssueOfStock
11500000
CY2020Q4 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
9900000
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1108374
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1108374
CY2020Q3 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family: times new roman; font-size: 10pt; margin-top: 18pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;;font-style:italic;display:inline;">Concentrations of Risk </div></div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: 'times new roman'; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of cash. The Company maintains deposits at federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2019Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
480000

Files In Submission

Name View Source Status
0001193125-20-292209-index-headers.html Edgar Link pending
0001193125-20-292209-index.html Edgar Link pending
0001193125-20-292209.txt Edgar Link pending
0001193125-20-292209-xbrl.zip Edgar Link pending
bntc-20200930.xml Edgar Link completed
bntc-20200930.xsd Edgar Link pending
bntc-20200930_cal.xml Edgar Link unprocessable
bntc-20200930_def.xml Edgar Link unprocessable
bntc-20200930_lab.xml Edgar Link unprocessable
bntc-20200930_pre.xml Edgar Link unprocessable
d943701d10q.htm Edgar Link pending
d943701dex311.htm Edgar Link pending
d943701dex312.htm Edgar Link pending
d943701dex321.htm Edgar Link pending
d943701dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending